Everly Health

Everly Health is an Austin, Texas-based digital health company built around diagnostic-driven care, combining at-home lab testing with telehealth services for both consumer and enterprise customers. Its consumer brand, Everlywell, sells self-collected lab test kits across categories including daily health (thyroid, cholesterol and lipids, inflammation, blood sugar, colon cancer screening), digestive health (food sensitivity panels covering up to 204 foods), sexual health (multi-infection STI panels, chlamydia and gonorrhea tests, rapid PCR tests) and hormone health (women's and men's hormone panels, cortisol). Products range from a $49 cholesterol and lipids test to higher-priced cancer screening offerings such as the Galleri multi-cancer early detection blood test at $949 and Caris Detect at $3,500, alongside a bundled 83-biomarker panel marketed as Everlywell 360. Kits have also been distributed through major retailers including Target, CVS and Walgreens.

The enterprise arm, Everly Health Solutions — the rebranded PWNHealth acquired in 2021 — operates a national clinician network and provides the clinical, legal and technological framework for population-scale testing programs for health plans, employers, providers and labs across all 50 states and Puerto Rico. Home Access Health Corporation, acquired at the same time, supplies self-collected lab tests to payers, providers and employers. At the time of the 2021 transactions the combined companies said they supported more than 20 million people annually across the United States, Canada and Puerto Rico and served over 350 clients.

The company received FDA authorization in May 2020 for a mail-in COVID-19 test and direct-to-consumer authorization for its COVID-19 home collection kit. It has since expanded through additional acquisitions, including women's health and fertility products company Natalist, and through partnerships that bring third-party screening tests such as Galleri, Caris Detect, Jona's gut microbiome test and Visby rapid PCR tests onto its platform.

Founding story

Everlywell was founded by Julia Cheek, who first presented the company publicly as a first-time founder around TechCrunch Disrupt in 2016 and launched consumer sales that year with PWNHealth as its partner of record for clinical oversight and telehealth. Cheek appeared on Shark Tank in 2018 and was later named to Forbes' list of America's richest self-made women with a net worth valued at $260 million.

Business model

Everly Health operates a dual consumer and enterprise model. On the consumer side it sells at-home sample-collection lab test kits and related virtual visits, vitamins and supplements directly through everlywell.com and through retail channels including Target, CVS and Walgreens. On the enterprise side, Everly Health Solutions provides diagnostic testing programs, telehealth network access and clinical oversight to health plans, employers, providers and labs, with more than 350 clients reported in 2021.

Revenue comes from per-kit and per-test sales to consumers, with published prices ranging from $49 for a cholesterol and lipids test to $949 for the Galleri multi-cancer early detection test and $3,500 for Caris Detect, plus bundled multi-biomarker offerings, virtual care visits and supplements. Enterprise revenue is generated from testing and engagement programs sold to health plans, healthcare organizations and employers. Consumer tests are described as generally eligible for payment with Flexible Spending and Health Savings Accounts.

Traction

At the March 2021 acquisition announcement the combined companies said they supported more than 20 million people annually across all 50 U.S. states, Canada and Puerto Rico, employed nearly 500 people and served over 350 clients; Everlywell reported over 300% revenue growth in the preceding year. By March 2022 headcount had grown to nearly 600 (from 88 in February 2020) and the company reported 100% year-over-year revenue growth, with non-COVID testing categories each growing over 100% in volume and some over 300%. In 2023 it was reported that Everlywell was the second highest revenue company in Shark Tank history.

Latest developments

The Everlywell storefront now features third-party and partner-branded screening products including the Caris Detect multi-cancer screening test ($3,500), the Galleri multi-cancer early detection blood test ($949), the Jona gut microbiome test with AI-generated recommendations ($485), and the Visby rapid PCR at-home female STD test ($149), alongside the Everlywell 360 program covering 83 biomarkers across six health categories.